Paper Details

  1. Home
  2. Paper Details

SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?

Author: AnnouschkaLaenen, BenVanneste, BenediktEngels, CarlSalembier, CharlienBerghen, CédericDraulans, FilipAmeye, GertDe Meerleer, HansVandendriessche, HerlindeDumez, Julieden Hartog, KarolienGoffin, KennethPoels, KoenSlabbaert, NickLiefhooghe, OlivierDe Hertogh, RansKato, StevenJoniau

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study discussed the use of metastasis-directed therapy (MDT) in patients with oligorecurrent prostate cancer (PCa), considering the potential for adding androgen deprivation therapy (ADT) to improve outcomes.
Paper Details　
Original Abstract of the Article :
Metastasis-directed therapy (MDT) significantly delays the initiation of palliative androgen deprivation therapy (pADT) in patients with oligorecurrent prostate cancer (PCa) with a positive impact on patient's quality of life. However, it remains unclear whether the addition of ADT improves polymeta...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743623/

データ提供：米国国立医学図書館（NLM）

SPARKLE: A New Approach to Treating Oligorecurrent Prostate Cancer

Prostate cancer, a common malignancy, can sometimes recur in a limited number of sites, a condition known as oligorecurrent prostate cancer. While metastasis-directed therapy (MDT) has shown promise in delaying the need for palliative androgen deprivation therapy (pADT) in these patients, the role of adding systemic treatment, such as androgen deprivation therapy (ADT), to MDT remains unclear. This research, published in [Journal Name], explores the potential of combining systemic treatment with MDT in treating oligorecurrent prostate cancer. The authors discuss the evidence supporting the use of ADT in combination with MDT, suggesting that this approach could improve polymetastatic free survival (PMFS) and metastatic castration refractory PCa-free survival (mCRPC-FS). They argue that further research is needed to optimize this combined approach and to determine the optimal duration of concomitant hormone therapy.

SPARKLE: A Promising Approach for Oligorecurrent Prostate Cancer

This research, published in [Journal Name], investigates the potential of combining systemic treatment with MDT in treating oligorecurrent prostate cancer. The authors suggest that this approach, termed SPARKLE, could offer a more effective treatment strategy, delaying disease progression and improving patient outcomes.

Navigating the Desert of Prostate Cancer

Prostate cancer can be as daunting as navigating a vast desert, with unpredictable challenges and potential setbacks. This research, published in [Journal Name], provides hope by exploring a new approach to treating oligorecurrent prostate cancer, offering a potential oasis in the desert of treatment options.

Dr.Camel's Conclusion

Just as a camel can traverse the desert, navigating its challenges with resilience, patients with oligorecurrent prostate cancer can find a path to improved outcomes with the SPARKLE approach. This research underscores the potential of combining systemic treatment with MDT, offering a beacon of hope in the desert of prostate cancer treatment.

Date :
  1. Date Completed 2022-12-16
  2. Date Revised 2022-12-21
Further Info :

Pubmed ID

36503429

DOI: Digital Object Identifier

PMC9743623

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.